Search
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Carisoprodol
go.drugbank.com/drugs/DB00395ApprovedThis drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications
Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateSIG-001
go.drugbank.com/drugs/DB17826InvestigationalSIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer
NADH
go.drugbank.com/drugs/DB00157ApprovedNutraceuticalIt forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed) … It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH).
Mixtures: EnlIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624] … [A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency.
alpha-Hydroxylinoleic acid
go.drugbank.com/drugs/DB16027Investigationalalpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIn animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551]. … Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.
Categories: Compounds used in a research, industrial, or household setting